doi:10.1007/s40618-019-01034-5 Iepsen EW, Lundgren JR, Hartmann B, et al
By improving the obesity status of patients, reducing weight, optimizing lipid metabolism, and exerting anti-inflammatory effects, GLP-1RAs may also play a positive role in cancer prevention and treatment
Important safety considerations include a boxed warning for medullary thyroid carcinoma (MTC) risk with most GLP-1 medications, which are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Ann Neurol (2021) 90(2):22738
Liraglutide In the LEAN study, the treatment efficacy and safety of the once-daily liraglutide (1.8 mg) were compared with those of the placebo after 48 weeks in 52 overweight patients with clinical evidence of NASH [12]